Clinical Trial Update: Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating continuation of cetuximab beyond first-line progression in metastatic colorectal cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 3 | Status: RECRUITING